Abstract:Background: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive drugs, or relapse after initial remission. Iguratimod is a novel disease modifying anti-rheumatic drug that has been approved for treating rheumatoid arthritis in East Asia and has shown benefits in lupus animal model in our previous research.(1) Objectives: The aim of the present study was to make a preliminary observation on the efficacy and safety of iguratimod in treating refractory LN patients. Methods: We have enrolled adult refractory LN patients who were eligible if they experienced at least two times of failure or relapse before enrollment. Failure was defined as no response to one certain immunosuppressive drug for at least six months. After enrollment, we simply switched their previous immunosuppressant to daily iguratimod (25 mg twice per day), while keeping all other medications. Complete/partial remission (PR/CR) was used as the primary outcome. 24h urine protein, blood cell counts, liver and kidney function were routinely monitored. Results: A total of 20 refractory LN patients had been enrolled (18 female and 2 male patients) since 2015. At enrollment, the median proteinuria was 2.588g/24h (range: 0.98-13.79g/24h). None of them had overt extra-renal involvement. All of them had biopsy-proven LN (class III/IV/V) and two patients agreed repeated biopsy before switching to iguratimod. The median prednisone dosage was 10mg/d (range: 5-35mg/d). One patient was lost to follow-up and one withdrew from the study. Of the remaining 18 patients, 16 patients achieved PR/CR and 2 did not respond to iguratimod. Of the 16 patients who achieved remission, 3 had renal relapse after initial PR and 1 had extra-renal flare after initial CR. One PR patient withdrew from the study due to severe anemia and another due to incompliance. For the remaining 10 patients who were still in follow-up, the median follow-up was 84 weeks (range: 28-144 weeks), with 4 having CR and 6 PR. The median response duration (MRD) was 12 weeks. Conclusion: Out study provided preliminary but promising clinical evidence for iguratimod in treating refractory LN patients. A large randomized clinical trial is needed to establish its safety and efficacy for refractory LN. References: [1] Yan Q, Du F, Huang X, Fu Q, Chen S, Dai D, et al. Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLoS One. 2014;9(10):e108273. Disclosure of Interests: None declared

Iguratimod Inhibits Renal Interstitial Fibrosis in Lupus Nephritis

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes

Iguratimod Alleviates Tubulo-Interstitial Injury in Mice with Lupus

Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice.

Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition

Iguratimod Ameliorates Nephritis by Modulating the Th17/Treg Paradigm in Pristane-Induced Lupus.

Iguratimod As an Alternative Induction Therapy for Refractory Lupus Nephritis: a Preliminary Investigational Study

IGURATIMOD MIGHT BE AN ALTERNATIVE OPTION FOR REFRACTORY LUPUS NEPHRITIS: A PRELIMINARY OBSERVATIONAL STUDY

Curcumin Attenuates Renal Interstitial Fibrosis of Obstructive Nephropathy by Suppressing Epithelial-Mesenchymal Transition Through Inhibition of the TLR4/NF-кB and PI3K/AKT Signalling Pathways.

LncRNA HOTAIR promotes renal interstitial fibrosis by regulating Notch1 pathway via the modulation of miR-124.

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells

IGFBP2 Function As a Novel Biomarker for Active Lupus Nephritis.

Icariin Alleviates Murine Lupus Nephritis Via Inhibiting NF-κB Activation Pathway and NLRP3 Inflammasome.

Curcumin Attenuates Lupus Nephritis by Inhibiting Neutrophil Migration Via PI3K/AKT/NF-κB Signalling Pathway

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction.

108 Iguratimod Inhibits Human B Cell Terminal Differentiation in Vitro and May Benefit Patients with Refractory Lupus Nephritis

Hirudin, a thrombin inhibitor, attenuates TGF-β-induced fibrosis in renal proximal tubular epithelial cells by inhibition of protease-activated receptor 1 expression via S1P/S1PR2/S1PR3 signaling

The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice

A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study